When the novel coronavirus (COVID-19) first emerged in Wuhan, China, several biopharmaceutical companies started working closely together with the Chinese governments and provided support on the bottom, in sort of donations of medicines, personal protective gear, diagnostic assay kits, and support. Latest developments throughout March have shown very few new cases in China and the majority of patients with COVID-19 have recovered or are on their way to recovery. With COVID-19 spreading globally, and particularly increasing cases across Europe, the biopharmaceutical industry is concentrating their efforts to accelerate R&D efforts into vaccines and treatments to halt the global spread of the virus.
By March 2020, China passed the peak of the COVID-19 with the number of new coronavirus cases continuing to decline while the epidemic maintains a “lower level” overall. By mid-March, the total number of cases and deaths outside China also overtook the total number of cases in China. Europe, and particularly Italy and Spain, and the United States are the most heavily affected areas of the pandemic by the end of March.
With China slowly resuming its economic and social life, the biopharmaceutical industry is concentrating their efforts to accelerate R&D efforts into vaccines and treatments to curb the global spread of the virus. Efforts on the ground, taking the form of donations or financial supplies, shifted by April to countries most affected in Europe, particularly Italy, and the United States.Playing our part in the fight against coronavirusDonate Now ₹100